ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

NCT07348107 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: ATRA
DRUG: Arsenic Trioxide (ATO)
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Tislelizumab

Sponsor

Daniel Breadner

Collaborators

[object Object]
[object Object]